627R649255T0 02 759 2000

FORM PTG 1390 DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFIC ATTORNEY'S DOCKET NUMBER 661-50303 TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CFR 1.5) N9//00906 CONCERNING A FILING UNDER 35 U.S.C. 371 PRIORITY DATE CLAIMED INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE 20 May 1999 22 May 1998 PCT/EP99/03451 TITLE OF INVENTION ANTISENSE OLIGONUCLEOTIDES FOR TREATING PROLIFERATING CELLS APPLICANT(S) FOR DO/EO/US Flad, Hans-Dieter; Bohle, Andreas; Deinert Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. This is an express request to promptly begin national examination procedures (35 U.S.C. 371(f)). The US has been elected by the expiration of 19 months from the priority date (PCT Article 31). A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is attached hereto (required only if not communicated by the International Bureau). X has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) are attached hereto (required only if not communicated by the International Bureau). have been communicated by the International Bureau. b. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11 to 16 below concern document(s) or information included: An Information Disclosure Statement under 37 CFR 1.97 and 1.98. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. A substitute specification. A change of power of attorney and/or address letter. Other items or information: Amend claims 4-8, 10 and 13 as follows, prior to calculating claim fees and without prejudice: Claim 4, line 1, delete "bis 3" Claim 5, line 1, delete "bis 4" Claim 6, line 1, delete "bis 5" Claim 7, line 1, delete "bis 6" Claim 8, line 1, delete "bis 7" Claim 10, line 1, delete "bis 8" Claim 13, line 1, delete "oder 12".

The Claims have been amended to remove multiple dependency only.

No claims have been amended to overcome prior art.

			492089	vaca - 21NA		
U.S. APPLICATION NO (16	97.7009	PCT/EP99/03451	o noo a i	ATTORNEYS DOC.		
17. X The following fees are submitted:  BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):				· CALCULATIONS	PTO USE ONLY	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$860.00						
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO						
International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4)						
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4)						
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$ 860		
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 x 30 months from the earliest claimed priority date (37 CFR 1.492(e)).				\$ 130		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE		T	
Total claims	15 - 20 = 3 - 3 =	0	X \$18.00	\$ ,		
Independent claims	L	O O	X \$80.00 + \$270.00	\$ \$		
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$270.00  TOTAL OF ABOVE CALCULATIONS =				\$ 990 ·		
Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$		
SUBTOTAL =				\$ 990		
Processing fee of \$130.00 for furnishing the English translation later than 20 × 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$ 130		
TOTAL NATIONAL FEE =				\$ 1,120		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +				\$		
TOTAL FEES ENCLOSED =				\$1,120		
				Amount to be refunded:	\$	
				charged:	\$1,120	
a. x A check in the amount of \$\frac{1,120}{}\$ to cover the above fees is enclosed.						
	b. Please charge my Deposit Account No in the amount of \$ to cover the above fees.  A duplicate copy of this sheet is enclosed.					
The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0687. A duplicate copy of this sheet is enclosed.  Under Order No.: 62-661						
		uit under 37 CFR 1.494 or 1.49 ed to restore the application to			vive (37 CFR	
SEND ALL CORRESPONDENCE TO:				U// m		
Customer No. 20736						
				rey S. Melcher		
			35,9	5.0		
				ATION NUMBER		
<b>9.</b>				L 21, 2000		
			worem	~ ~ 1 2000		

## PTO RECEIPT FOR INDICATED ITEMS

Transmittal Letter to US Designated Office Concerning Filing Under 35 USC 371

International Application No.: PCT/EP99/03451

Inventor: Flad

Title: Antisense Oligonucleotides for Treating Proliferating Cells

Attorney Docket No.: 661-50303

Preliminary Amendment

Fee Sheet

Check for \$1,120.

The PTO did not receive the following

listed item(s)

Current Due Date: November 22, 2000

21 NOV 2000